GMP IPO
📋 Filings Intelligence
About Contact
LIVE - Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement - financial results, order wins, dividends, mergers and more. Updated live.

-
Filed today
-
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings -

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Tavexia Lifecare Ltd

Tavexia Lifecare to Raise Rs. 68 Crore for Meyonex Acquisition

FUNDRAISE ◆ Monitor Closely MEDIUM RISK
📅 Filed on BSE: 04 Nov 2026, 09:28 PM IST  ·  BSE ID: 1f29842b-401c-404c-bb57-d1943ecd4f66
View Original BSE Filing (PDF)
💡
In Simple Terms
The company plans to raise up to Rs. 68 crore by selling new shares to buy a majority stake in another pharmaceutical firm.
🤖 AI Summary
  • Board approved raising up to Rs. 68,00,00,000 for Meyonex Pharmaceuticals acquisition.
  • Approved un-audited financial results for Q2 FY27 and half-year ended September 30, 2026.
  • Considered statement of deviation(s) on use of proceeds from the Right Issue.
  • Approved change of Registrar and Transfer Agent to Skyline Financial Services.
🔢 Key Numbers - exact figures from BSE filing, not rounded
Fundraising Amount
Rs. 68,00,00,000
Acquisition Stake
60%
Financial Period End
September 30, 2026
🏢 How This Affects the Company
📈
Business Impact
The proposed fundraise is to acquire a 60% stake in Meyonex Pharmaceuticals, which could expand Tavexia Lifecare's pharmaceutical segment.
💰
Financial Impact
The company plans to raise up to Rs. 68,00,00,000, impacting its capital structure and potentially increasing its asset base post-acquisition.
⚙️
Operational Impact
A change in Registrar and Transfer Agent will occur, transitioning from Niche Technologies to Skyline Financial Services.
⚠️
Risk Impact
The fundraise for acquisition introduces execution risk related to the integration of Meyonex Pharmaceuticals and the success of the capital raising.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required from shareholders.
👤
Who Is Affected
All existing shareholders are potentially affected by the proposed equity issuance and acquisition.
🔍
Management Signal
Management is signalling intent to pursue strategic growth through acquisitions in the pharmaceutical sector.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List - track these upcoming events
Details of fund raising mode and final approval
Completion of Meyonex Pharmaceuticals acquisition
Q3 FY27 financial results announcement
MEDIUM RISK Fundraising is in-principle, acquisition terms and execution carry execution risk.
💡 Investor Takeaway
Tavexia Lifecare's Board has approved a proposal to raise up to Rs. 68,00,00,000 to fund its acquisition of 60% of Meyonex Pharmaceuticals.
⚖️ Strengths & Concerns

✅ Positives

  • Board approved fundraising of up to Rs. 68,00,00,000 for strategic acquisition.
  • Unaudited financial results for Q2 FY27 and half-year ended September 30, 2026, approved.

⚠️ Concerns

  • Fundraising is in 'in-principle' stage, final mode and terms to be decided in a subsequent meeting.
  • Details of deviation(s) or variation(s) on use of Right Issue proceeds to be considered.
📅 Company Track Record
Previously known as Sattva Sukun Lifecare Limited, the company previously confirmed no rights issue fund deviation in its Q1 FY27 results.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What is the proposed amount Tavexia Lifecare plans to raise?
The Board has approved a proposal to raise an aggregate amount not exceeding Rs. 68,00,00,000.
What is the purpose of Tavexia Lifecare's proposed fundraise?
The funds are intended to finance the proposed acquisition of 60% of the equity share capital of Meyonex Pharmaceuticals Limited.
What financial results did Tavexia Lifecare's Board approve?
The Board approved the Un-Audited Financial Results (Standalone and consolidated) for the Quarter and half year ended September 30, 2026.
Who is the new Registrar and Transfer Agent for Tavexia Lifecare?
The company approved changing its Registrar & Transfer Agent from Niche Technologies Pvt. Ltd to Skyline Financial Services Pvt. Ltd.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again - explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only - Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector - takes 5 seconds.